ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

ClinicalTrials.gov ID: NCT00944047

Public ClinicalTrials.gov record NCT00944047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)

Study identification

NCT ID
NCT00944047
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
University of Kansas Medical Center
Other
Enrollment
32 participants

Conditions and interventions

Conditions

Interventions

  • Doxorubicin Drug
  • Growth Factor Support Biological
  • Surgery Procedure
  • cyclophosphamide Drug
  • nab-paclitaxel Drug
  • trastuzumab Drug

Drug · Biological · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2009
Primary completion
Apr 30, 2014
Completion
Jul 31, 2017
Last update posted
Apr 22, 2018

2009 – 2017

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
Hays Medical Center Hays Kansas 67601
University of Kansas Medical Center Cancer Center Kansas City Kansas 66205

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00944047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2018 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00944047 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →